查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
2008352

神经科学市场：依产品类型、技术、应用和最终用户划分－2026-2032年全球市场预测

Neuroscience Market by Product Type, Technology, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 193 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，神经科学市场价值将达到 167.7 亿美元，到 2026 年将成长到 186.1 亿美元，到 2032 年将达到 341.5 亿美元，复合年增长率为 10.69%。

主要市场统计数据
基准年 2025 167.7亿美元
预计年份：2026年 186.1亿美元
预测年份 2032 341.5亿美元
复合年增长率 (%) 10.69%

对当前神经科学趋势的简要概述，抓住塑造技术创新、相关人员合作和临床应用的策略转折点。

神经科学生态系统正处于快速技术创新和临床范式转变的交汇点，促使产业界、学术界和医疗服务机构的领导者重新评估优先事项和投资策略。影像解析度、讯号处理和演算法解读的进步使得更精准的诊断和更精细的治疗性介入成为可能，而工程师、临床医生和资料科学家之间日益密切的跨学科合作也加速了转化研究的进程。同时，医疗系统正努力应对不断变化的报销机制和日益增长的基于价值的治疗结果期望，尤其关注可验证的临床效用和成本效益。

详细概述了推动神经科学研究和临床实践模式转移的技术、监管和商业的融合力量。

在技​​术成熟、监管演变和相关人员期望转变这三大相互关联的趋势的驱动下，一场突破性的变革正在进行，它正在重新定义神经科学领域的竞争格局和临床实践。在技​​术层面，高解析度磁振造影和先进的脑电图平台等技术的进步提高了诊断准确性，并促进了新生物标记的发现。同时，从先进的分析流程到视觉化套件，软体的同步改进正在加速从发现到临床决策的进程，将原始数据转化为可操作的洞见。

对 2025 年关税调整将如何重塑神经科学技术提供者的供应链策略、采购选择和业务永续营运进行全面分析。

2025年实施的关税和贸易调整措施，为支持神经科学技术的供应链增添了新的复杂性，对采购、製造和服务交付等各个环节都产生了累积影响。进口零件和成品关税的提高，促使许多供应商重新评估其供应商所在地，并考虑采取地域多元化策略，以保护自身业务免受贸易波动的影响。实际上，采购团队面临着不断上涨的到货成本和更长的前置作业时间，这要求他们在库存管理和合约条款方面进行策略性调整，以确保向临床客户和研究合作伙伴持续供应产品。

将产品层级、模式技术、临床应用和买家类型连结起来的多维细分框架，能够制定针对每个产业的商业化策略。

细分市场分析揭示了产品、技术、应用和最终用户这四个类别各自需要不同的策略和专业化的服务。依产品类型，市场可分为「设备」、「服务」及「软体」三大类。其中，设备包括「影像设备」、「监测设备」和「治疗设备」。影像设备涵盖多种模式，例如电脑断层扫描 (CT) 扫描仪、脑电图 (EEG) 扫描仪和磁振造影(MRI) 扫描仪，每种模式都需要不同的开发蓝图和临床检验流程。监测设备分为侵入性监测设备和非侵入性监测设备，每种设备都有不同的监管要求和临床实施考量。治疗设备包括神经调控设备和復健设备，这些设备需要强有力的证据证明其具有持续的治疗效果，并需要明确的患者选择标准。服务进一步细分为咨询服务和维护服务，体现了咨询能力在临床实施和售后支援中的重要性。软体包括分析软体和视觉化软体，互通性、监管分类和使用者体验是实施的关键因素。

对美洲、欧洲、中东和非洲以及亚太地区的采用趋势、监管环境和商业化重点进行战略区域展望。

区域趋势对策略重点、监管方式和临床部署速度有显着影响。在美洲，创新中心和成熟的临床研究网络正在推动先进成像和监测设备的早期应用。同时，健保报销机制和大规模综合医疗服务网络正在影响采购计划和对成熟价值的需求。临床试验活动以及与製药研发公司的合作也催生了对研究设备和分析平台的需求。

这项企业级分析重点阐述了硬体、软体和服务的集成，以及证据和互通性如何推动竞争差异化。

企业层面的关键洞察揭示了一个日益由差异化驱动的竞争格局，这种差异化体现在整合解决方案、证据产生和卓越的售后服务上。领先的医疗设备製造商正在投资高解析度硬体和模组化平台，以支援多模态成像和高效的升级路径，从而建立长期的客户关係并减少整个生命週期中的摩擦。同时，专业软体公司正透过提供先进的分析引擎和以使用者为中心的视觉化工具来扩大其影响力，这些工具可以缩短解读时间并提高诊断信心。

为领导者提供具体可行的策略和营运建议，以加速临床应用、增强韧性、产生证据并加强综合经营模式。

产业领导者应推动一系列切实可行的倡议，将洞察转化为营运优势。首先，他们需要对产品组合进行策略性优先排序，使产品开发资源与具有高影响力的临床应用以及支援这些应用的监管路径相符。优先事项应包括增强资料互通性、投资于能够证明实际应用效益的可靠检验研究，以及设计将医疗设备、分析和服务整合在一起的灵活商业模式。这将有助于各机构减少临床实践中的摩擦，并更好地满足支付方和医疗服务提供者的期望。

采用透明、多方面的研究途径，结合专家访谈、文献整合和情境分析，检验研究结果，并支持可操作的结论。

本分析的调查方法结合了定性和定量方法，以确保研究的严谨性和有效性。主要调查包括对临床医生、监管专家、采购经理和研发主管等领域专家进行结构化访谈，以收集第一线专家的观点。次要调查包括对同行评审文献、监管指导文件、临床试验註册资讯和公开文件进行系统性回顾，以全面检验研究结果并确定特定技术方面的考虑因素，例如治疗模式的性能和实施要求。

这项具有前瞻性的综合分析概述了技术的整合、检验和稳健实施如何决定神经科学领域的竞争优势和临床影响。

总之，在技术进步、法规结构转变和不断变化的商业性预期等因素的驱动下，神经科学领域正进入一个加速转型期。医疗设备创新、先进软体功能和增强服务模式的相互作用，正为更早的诊断、更精准的监测和更有效的治疗方法铺平道路。儘管供应链调整和区域监管趋势日益复杂，但也为透过在地化生产、卓越的服务网络和针对性证据的创建实现策略差异化提供了机会。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：神经科学市场：依产品类型划分

  • 医疗设备
    • 医疗影像设备
      • 电脑断层扫描器
      • 脑电图（EEG）测量设备
      • 磁振造影系统
    • 监控设备
      • 侵入式监测设备
      • 非侵入式监测设备
    • 治疗设备
      • 神经控制装置
      • 復健设备
  • 服务
    • 咨询服务
    • 维护服务
  • 软体
    • 分析软体
    • 视觉化软体

第九章：神经科学市场：依技术划分

  • 电脑断层扫描
  • 脑电图（EEG）
  • 功能性近红外线光谱
  • 磁振造影
  • 脑磁图

第十章：神经科学市场：依应用领域划分

  • 诊断
    • 心血管疾病
    • 神经系统疾病
    • 肿瘤影像
  • 监测
  • 调查
  • 治疗
    • 神经调控
    • 復健治疗

第十一章 神经科学市场：依最终用户划分

  • 诊所
  • 医院
  • 製药公司
  • 研究机构

第十二章 神经科学市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章：神经科学市场：依群体划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章 神经科学市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章：美国神经科学市场

第十六章：中国神经科学市场

第十七章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Abbott Laboratories
  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca PLC
  • Biogen Inc.
  • Blackrock Neurotech
  • DeepMind Technologies
  • Eli Lilly and Company
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Neurocrine Biosciences, Inc.
  • NeuroPace
  • Novartis AG
  • Pfizer Inc.
  • Roche Holding AG
  • Sanofi SA
  • Teva Pharmaceutical Industries Ltd
Product Code: MRR-C002B1C9955F

The Neuroscience Market was valued at USD 16.77 billion in 2025 and is projected to grow to USD 18.61 billion in 2026, with a CAGR of 10.69%, reaching USD 34.15 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 16.77 billion
Estimated Year [2026] USD 18.61 billion
Forecast Year [2032] USD 34.15 billion
CAGR (%) 10.69%

A concise overview of the current neuroscience landscape capturing technological innovation, stakeholder convergence, and the strategic inflection points shaping clinical adoption

The neuroscience ecosystem stands at the intersection of rapid technological innovation and shifting clinical paradigms, prompting leaders across industry, academia, and healthcare delivery to reassess priorities and investment theses. Advances in imaging resolution, signal processing, and algorithmic interpretation are enabling more precise diagnostics and refined therapeutic interventions, while growing interdisciplinary collaboration between engineers, clinicians, and data scientists accelerates translational progress. Concurrently, health systems are contending with evolving reimbursement frameworks and heightened expectations for value-based outcomes, which places a premium on demonstrable clinical utility and cost-effectiveness.

Throughout this report, we emphasize the convergence of device innovation, software sophistication, and service models that together reshape how neurological conditions are detected, monitored, and treated. The introductory analysis synthesizes key drivers such as regulatory pathways that incentivize safety and performance, advances in analytics that unlock latent clinical signals, and operational demands that require scalable maintenance and consultancy support. By clarifying these forces, readers will gain a cohesive understanding of the current landscape and the strategic inflection points that will determine competitive advantage in the near to medium term.

An in-depth synthesis of converging technological, regulatory, and commercial forces that are driving paradigm shifts across neuroscience research and clinical practice

Significant transformative shifts are redefining competitive dynamics and clinical practice within neuroscience, driven by three interrelated currents: technological maturation, regulatory evolution, and shifting stakeholder expectations. On the technology front, enhancements in modalities such as high-resolution magnetic resonance techniques and advanced electroencephalography platforms are expanding diagnostic clarity and enabling novel biomarkers. Parallel improvements in software, from advanced analysis pipelines to visualization suites, are converting raw data into actionable insights, thereby accelerating the path from discovery to clinical decision-making.

Regulatory frameworks are evolving to accommodate software as a medical device and hybrid hardware-software systems, which incentivizes rigorous validation and post-market surveillance while creating clearer pathways for safer deployment. Simultaneously, purchasers and care providers are prioritizing real-world evidence and demonstrable outcomes, driving vendors to integrate services such as consultancy and maintenance into their value propositions. As a result, business models are shifting from product-centric sales to outcome-oriented solutions, with bundled offerings that combine devices, analysis software, and ongoing support gaining traction. These shifts are spurring new partnerships across device manufacturers, clinical research organizations, and analytics firms, ultimately accelerating adoption in clinical and research settings.

A comprehensive analysis of how 2025 tariff adjustments have reshaped supply chain strategies, sourcing choices, and operational resilience across neuroscience technology providers

The imposition of tariffs and trade adjustments in 2025 introduced a layer of complexity for supply chains that underpin neuroscience technologies, with cumulative impacts felt across sourcing, manufacturing, and service delivery. Increased duties on imported components and finished goods have led many suppliers to reassess supplier footprints and to consider regional diversification strategies to insulate operations from trade volatility. In practice, procurement teams face higher landed costs and longer lead times, prompting strategic shifts in inventory management and contractual terms to preserve continuity for clinical customers and research partners.

In response, several manufacturers have accelerated nearshoring and re-shoring initiatives, moving certain assembly and calibration activities closer to primary end markets to mitigate tariff exposure and reduce transit-related disruption. These changes have required capital investment and operational retooling, as well as renewed focus on supplier qualification and local regulatory compliance. Moreover, service providers that rely on cross-border technician mobility and spare-part exchanges have had to adapt service models, investing in local technician training and regional parts depots to maintain responsiveness. Taken together, these adaptations highlight the need for flexible supply chain strategies that balance cost, compliance, and uptime in the face of evolving trade policy.

A multidimensional segmentation framework linking product hierarchies, modality technologies, clinical applications, and purchaser types to inform tailored commercialization strategies

Segmentation analysis illuminates how distinct product, technology, application, and end-user categories demand tailored strategies and specialized offerings. Based on Product Type, the market can be parsed into Devices, Services, and Software, with Devices encompassing Imaging Devices, Monitoring Devices, and Therapeutic Devices. Within Imaging Devices, modalities such as Computed Tomography Devices, Electroencephalography Devices, and Magnetic Resonance Imaging Devices require differentiated development roadmaps and clinical validation pathways. Monitoring Devices break down into Invasive Monitoring Devices and Non Invasive Monitoring Devices, each presenting divergent regulatory requirements and clinical deployment considerations. Therapeutic Devices include Neuromodulation Devices and Rehabilitation Devices, which necessitate strong evidence of sustained outcomes and clear patient selection criteria. Services further subdivide into Consultancy Services and Maintenance Services, reflecting the importance of advisory capabilities and post-sale support for clinical integration. Software comprises Analysis Software and Visualization Software, where interoperability, regulatory classification, and user experience are critical adoption levers.

Based on Technology, offerings span Computed Tomography, Electroencephalography, Functional Near Infrared Spectroscopy, Magnetic Resonance Imaging, and Magnetoencephalography, each technology bringing specific sensitivity profiles, requirements for shielding and environment control, and distinct data management needs. Based on Application, the landscape includes Diagnostics, Monitoring, Research, and Therapy, with Diagnostics further focused on cardiovascular disorders, neurological disorders, and oncology imaging, while Therapy emphasizes neuromodulation and rehabilitation therapy. Each application area imposes unique clinical utility thresholds and evidence requirements, influencing product development and commercialization strategies. Based on End User, primary purchasers include Clinics, Hospitals, Pharmaceutical Companies, and Research Institutes, and each end user type shows different procurement cycles, capital planning horizons, and expectations for integration and service levels. When considered together, these segmentation layers provide a multidimensional framework that supports nuanced go-to-market decisions, prioritization of R&D efforts, and the design of tailored commercial models aimed at accelerating adoption across diverse customer profiles.

Strategic regional perspectives on adoption dynamics, regulatory landscapes, and commercialization priorities across the Americas, Europe Middle East & Africa, and Asia Pacific

Regional dynamics exert a profound influence on strategic priorities, regulatory approaches, and the pace of clinical adoption. In the Americas, innovation hubs and established clinical research networks drive early adoption of advanced imaging and monitoring devices, while reimbursement environments and large integrated delivery networks shape procurement timetables and demand for demonstrated value. Clinical trial activity and collaborations with pharmaceutical developers also create demand for research-grade instrumentation and analytics platforms.

In Europe, the Middle East & Africa, regulatory harmonization efforts and centralized health technology assessment bodies influence the evaluation criteria for new technologies, and heterogeneous reimbursement pathways require customized market access strategies. Additionally, public healthcare systems in several countries prioritize cost-effectiveness and scalability, prompting suppliers to emphasize total cost of ownership and service reliability. The Asia-Pacific region is characterized by rapid infrastructure investment, growing clinical research capacity, and diverse adoption curves across countries. Markets in this region often present opportunities for localized manufacturing, partnerships with academic centers, and tailored training programs to support clinical adoption. Across these regions, strategic considerations include supply chain localization, alignment with regional regulatory expectations, and the development of culturally appropriate training and support materials to ensure successful deployment and sustained use.

Company-level analysis highlighting how integration of hardware, software, and services combined with evidence and interoperability drives competitive differentiation

Key company-level insights reveal a competitive landscape where differentiation is increasingly driven by integrated solutions, evidence generation, and after-sales service excellence. Leading device manufacturers are investing in higher-resolution hardware and modular platforms that support multi-modal imaging and streamlined upgrade paths, enabling long-term customer relationships and reduced lifecycle friction. At the same time, specialized software firms are gaining influence by delivering advanced analysis engines and user-centric visualization tools that reduce interpretation time and enhance diagnostic confidence.

Partnerships between hardware vendors and analytics providers are becoming more commonplace, creating bundled offerings that combine devices, analysis software, and consultancy services to accelerate clinical adoption. Service organizations that can demonstrate rapid deployment capabilities, robust maintenance networks, and regionally accredited training programs are achieving competitive advantage by minimizing downtime and supporting consistent outcomes. Firms that prioritize interoperability, data security, and compliance with evolving regulatory expectations are better positioned to secure large institutional contracts. Collectively, these company-level trends underscore the importance of cross-functional coordination between R&D, regulatory affairs, clinical affairs, and commercial teams to translate technical innovation into sustained market impact.

Actionable strategic and operational recommendations for leaders to strengthen resilience, evidence generation, and integrated commercial models that accelerate clinical adoption

Industry leaders should pursue a set of pragmatic actions to translate insights into operational advantage, beginning with strategic portfolio prioritization that aligns product development resources with high-impact clinical applications and supportive regulatory pathways. Priorities should include strengthening data interoperability, investing in robust validation studies that demonstrate real-world clinical benefit, and designing flexible commercial models that bundle devices, analytics, and services. By doing so, organizations can reduce friction at the point of care and better align with payer and provider expectations.

Operationally, firms should accelerate supply chain resilience initiatives, including diversification of component sourcing, establishment of regional service hubs, and investment in local technician training programs to maintain uptime in the face of trade or logistics disruptions. Commercial teams ought to develop tailored go-to-market approaches for distinct end-user segments, offering differentiated value propositions for clinics, hospitals, pharmaceutical companies, and research institutes. Moreover, forging strategic alliances with early adopter institutions and academic centers can produce the clinical evidence and case studies needed to scale adoption. Finally, leaders should actively monitor regulatory trends and participate in standards-setting forums to shape policy and ensure smoother market entry for integrated hardware-software solutions.

A transparent, multi-method research approach combining expert interviews, literature synthesis, and scenario analysis to validate findings and support actionable conclusions

The research methodology underpinning this analysis combines qualitative and quantitative approaches to ensure rigor and relevance. Primary research included structured interviews with domain experts encompassing clinicians, regulatory specialists, procurement leaders, and R&D executives to capture on-the-ground perspectives. Secondary research comprised a systematic review of peer-reviewed literature, regulatory guidance documents, clinical trial registries, and public filings to triangulate findings and verify technology-specific considerations such as modality performance and deployment requirements.

Analytical techniques applied include comparative technology assessments, value-chain mapping, and scenario analysis to evaluate the implications of policy changes and supply chain disruptions. Evidence synthesis prioritized reproducibility and transparency, with clear documentation of data sources, inclusion criteria, and assumptions used in qualitative interpretation. In addition, iterative validation workshops with subject-matter experts were conducted to test preliminary conclusions and enhance the practical applicability of recommendations. Collectively, these methods provide a robust foundation for insights that are both evidence-based and actionable within clinical, research, and commercial contexts.

A forward-looking synthesis outlining how integration of technology, validation, and resilient operations will determine competitive advantage and clinical impact in neuroscience

In conclusion, the neuroscience sector is navigating a period of accelerated transformation driven by technological advances, shifting regulatory frameworks, and evolving commercial expectations. The interplay between device innovation, sophisticated software capabilities, and enhanced service models is creating new pathways for earlier diagnosis, more precise monitoring, and more effective therapies. Supply chain adjustments and regional regulatory dynamics add complexity but also present opportunities for strategic differentiation through localized manufacturing, superior service networks, and targeted evidence generation.

Looking ahead, organizations that prioritize integrated solutions, invest in rigorous clinical validation, and cultivate resilient operational models will be best positioned to capture emerging opportunities. Cross-sector collaboration, informed by transparent data-sharing practices and interoperability standards, will accelerate adoption and improve patient outcomes. By synthesizing the insights presented across these sections, decision-makers can develop focused strategies to navigate uncertainty, align resources with clinical needs, and deliver sustainable value to patients and healthcare systems.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Neuroscience Market, by Product Type

  • 8.1. Devices
    • 8.1.1. Imaging Devices
      • 8.1.1.1. Computed Tomography Devices
      • 8.1.1.2. Electroencephalography Devices
      • 8.1.1.3. Magnetic Resonance Imaging Devices
    • 8.1.2. Monitoring Devices
      • 8.1.2.1. Invasive Monitoring Devices
      • 8.1.2.2. Non Invasive Monitoring Devices
    • 8.1.3. Therapeutic Devices
      • 8.1.3.1. Neuromodulation Devices
      • 8.1.3.2. Rehabilitation Devices
  • 8.2. Services
    • 8.2.1. Consultancy Services
    • 8.2.2. Maintenance Services
  • 8.3. Software
    • 8.3.1. Analysis Software
    • 8.3.2. Visualization Software

9. Neuroscience Market, by Technology

  • 9.1. Computed Tomography
  • 9.2. Electroencephalography
  • 9.3. Functional Near Infrared Spectroscopy
  • 9.4. Magnetic Resonance Imaging
  • 9.5. Magnetoencephalography

10. Neuroscience Market, by Application

  • 10.1. Diagnostics
    • 10.1.1. Cardiovascular Disorders
    • 10.1.2. Neurological Disorders
    • 10.1.3. Oncology Imaging
  • 10.2. Monitoring
  • 10.3. Research
  • 10.4. Therapy
    • 10.4.1. Neuromodulation
    • 10.4.2. Rehabilitation Therapy

11. Neuroscience Market, by End User

  • 11.1. Clinics
  • 11.2. Hospitals
  • 11.3. Pharmaceutical Companies
  • 11.4. Research Institutes

12. Neuroscience Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Neuroscience Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Neuroscience Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Neuroscience Market

16. China Neuroscience Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Abbott Laboratories
  • 17.6. AbbVie Inc.
  • 17.7. Amgen Inc.
  • 17.8. AstraZeneca PLC
  • 17.9. Biogen Inc.
  • 17.10. Blackrock Neurotech
  • 17.11. DeepMind Technologies
  • 17.12. Eli Lilly and Company
  • 17.13. Johnson & Johnson
  • 17.14. Merck & Co., Inc.
  • 17.15. Neurocrine Biosciences, Inc.
  • 17.16. NeuroPace
  • 17.17. Novartis AG
  • 17.18. Pfizer Inc.
  • 17.19. Roche Holding AG
  • 17.20. Sanofi S.A.
  • 17.21. Teva Pharmaceutical Industries Ltd

LIST OF FIGURES

  • FIGURE 1. GLOBAL NEUROSCIENCE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL NEUROSCIENCE MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL NEUROSCIENCE MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL NEUROSCIENCE MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL NEUROSCIENCE MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL NEUROSCIENCE MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL NEUROSCIENCE MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL NEUROSCIENCE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL NEUROSCIENCE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL NEUROSCIENCE MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES NEUROSCIENCE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA NEUROSCIENCE MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL NEUROSCIENCE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL NEUROSCIENCE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL NEUROSCIENCE MARKET SIZE, BY DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL NEUROSCIENCE MARKET SIZE, BY DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL NEUROSCIENCE MARKET SIZE, BY DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL NEUROSCIENCE MARKET SIZE, BY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL NEUROSCIENCE MARKET SIZE, BY IMAGING DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL NEUROSCIENCE MARKET SIZE, BY IMAGING DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL NEUROSCIENCE MARKET SIZE, BY IMAGING DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL NEUROSCIENCE MARKET SIZE, BY IMAGING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL NEUROSCIENCE MARKET SIZE, BY COMPUTED TOMOGRAPHY DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL NEUROSCIENCE MARKET SIZE, BY COMPUTED TOMOGRAPHY DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL NEUROSCIENCE MARKET SIZE, BY COMPUTED TOMOGRAPHY DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL NEUROSCIENCE MARKET SIZE, BY ELECTROENCEPHALOGRAPHY DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL NEUROSCIENCE MARKET SIZE, BY ELECTROENCEPHALOGRAPHY DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL NEUROSCIENCE MARKET SIZE, BY ELECTROENCEPHALOGRAPHY DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL NEUROSCIENCE MARKET SIZE, BY MAGNETIC RESONANCE IMAGING DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL NEUROSCIENCE MARKET SIZE, BY MAGNETIC RESONANCE IMAGING DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL NEUROSCIENCE MARKET SIZE, BY MAGNETIC RESONANCE IMAGING DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL NEUROSCIENCE MARKET SIZE, BY MONITORING DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL NEUROSCIENCE MARKET SIZE, BY MONITORING DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL NEUROSCIENCE MARKET SIZE, BY MONITORING DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL NEUROSCIENCE MARKET SIZE, BY MONITORING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL NEUROSCIENCE MARKET SIZE, BY INVASIVE MONITORING DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL NEUROSCIENCE MARKET SIZE, BY INVASIVE MONITORING DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL NEUROSCIENCE MARKET SIZE, BY INVASIVE MONITORING DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL NEUROSCIENCE MARKET SIZE, BY NON INVASIVE MONITORING DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL NEUROSCIENCE MARKET SIZE, BY NON INVASIVE MONITORING DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL NEUROSCIENCE MARKET SIZE, BY NON INVASIVE MONITORING DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL NEUROSCIENCE MARKET SIZE, BY THERAPEUTIC DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL NEUROSCIENCE MARKET SIZE, BY THERAPEUTIC DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL NEUROSCIENCE MARKET SIZE, BY THERAPEUTIC DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL NEUROSCIENCE MARKET SIZE, BY THERAPEUTIC DEVICES, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL NEUROSCIENCE MARKET SIZE, BY NEUROMODULATION DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL NEUROSCIENCE MARKET SIZE, BY NEUROMODULATION DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL NEUROSCIENCE MARKET SIZE, BY NEUROMODULATION DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL NEUROSCIENCE MARKET SIZE, BY REHABILITATION DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL NEUROSCIENCE MARKET SIZE, BY REHABILITATION DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL NEUROSCIENCE MARKET SIZE, BY REHABILITATION DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL NEUROSCIENCE MARKET SIZE, BY SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL NEUROSCIENCE MARKET SIZE, BY SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL NEUROSCIENCE MARKET SIZE, BY SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL NEUROSCIENCE MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL NEUROSCIENCE MARKET SIZE, BY CONSULTANCY SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL NEUROSCIENCE MARKET SIZE, BY CONSULTANCY SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL NEUROSCIENCE MARKET SIZE, BY CONSULTANCY SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL NEUROSCIENCE MARKET SIZE, BY MAINTENANCE SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL NEUROSCIENCE MARKET SIZE, BY MAINTENANCE SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL NEUROSCIENCE MARKET SIZE, BY MAINTENANCE SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL NEUROSCIENCE MARKET SIZE, BY SOFTWARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL NEUROSCIENCE MARKET SIZE, BY SOFTWARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL NEUROSCIENCE MARKET SIZE, BY SOFTWARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL NEUROSCIENCE MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL NEUROSCIENCE MARKET SIZE, BY ANALYSIS SOFTWARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL NEUROSCIENCE MARKET SIZE, BY ANALYSIS SOFTWARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL NEUROSCIENCE MARKET SIZE, BY ANALYSIS SOFTWARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL NEUROSCIENCE MARKET SIZE, BY VISUALIZATION SOFTWARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL NEUROSCIENCE MARKET SIZE, BY VISUALIZATION SOFTWARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL NEUROSCIENCE MARKET SIZE, BY VISUALIZATION SOFTWARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL NEUROSCIENCE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL NEUROSCIENCE MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL NEUROSCIENCE MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL NEUROSCIENCE MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL NEUROSCIENCE MARKET SIZE, BY ELECTROENCEPHALOGRAPHY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL NEUROSCIENCE MARKET SIZE, BY ELECTROENCEPHALOGRAPHY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL NEUROSCIENCE MARKET SIZE, BY ELECTROENCEPHALOGRAPHY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL NEUROSCIENCE MARKET SIZE, BY FUNCTIONAL NEAR INFRARED SPECTROSCOPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL NEUROSCIENCE MARKET SIZE, BY FUNCTIONAL NEAR INFRARED SPECTROSCOPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL NEUROSCIENCE MARKET SIZE, BY FUNCTIONAL NEAR INFRARED SPECTROSCOPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL NEUROSCIENCE MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL NEUROSCIENCE MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL NEUROSCIENCE MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL NEUROSCIENCE MARKET SIZE, BY MAGNETOENCEPHALOGRAPHY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL NEUROSCIENCE MARKET SIZE, BY MAGNETOENCEPHALOGRAPHY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL NEUROSCIENCE MARKET SIZE, BY MAGNETOENCEPHALOGRAPHY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL NEUROSCIENCE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL NEUROSCIENCE MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL NEUROSCIENCE MARKET SIZE, BY DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL NEUROSCIENCE MARKET SIZE, BY DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL NEUROSCIENCE MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL NEUROSCIENCE MARKET SIZE, BY CARDIOVASCULAR DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL NEUROSCIENCE MARKET SIZE, BY CARDIOVASCULAR DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL NEUROSCIENCE MARKET SIZE, BY CARDIOVASCULAR DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL NEUROSCIENCE MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL NEUROSCIENCE MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL NEUROSCIENCE MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL NEUROSCIENCE MARKET SIZE, BY ONCOLOGY IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL NEUROSCIENCE MARKET SIZE, BY ONCOLOGY IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL NEUROSCIENCE MARKET SIZE, BY ONCOLOGY IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL NEUROSCIENCE MARKET SIZE, BY MONITORING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL NEUROSCIENCE MARKET SIZE, BY MONITORING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL NEUROSCIENCE MARKET SIZE, BY MONITORING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL NEUROSCIENCE MARKET SIZE, BY RESEARCH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL NEUROSCIENCE MARKET SIZE, BY RESEARCH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL NEUROSCIENCE MARKET SIZE, BY RESEARCH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL NEUROSCIENCE MARKET SIZE, BY THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL NEUROSCIENCE MARKET SIZE, BY THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL NEUROSCIENCE MARKET SIZE, BY THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL NEUROSCIENCE MARKET SIZE, BY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL NEUROSCIENCE MARKET SIZE, BY NEUROMODULATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL NEUROSCIENCE MARKET SIZE, BY NEUROMODULATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL NEUROSCIENCE MARKET SIZE, BY NEUROMODULATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL NEUROSCIENCE MARKET SIZE, BY REHABILITATION THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL NEUROSCIENCE MARKET SIZE, BY REHABILITATION THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL NEUROSCIENCE MARKET SIZE, BY REHABILITATION THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL NEUROSCIENCE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL NEUROSCIENCE MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL NEUROSCIENCE MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL NEUROSCIENCE MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL NEUROSCIENCE MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL NEUROSCIENCE MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL NEUROSCIENCE MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL NEUROSCIENCE MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL NEUROSCIENCE MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL NEUROSCIENCE MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL NEUROSCIENCE MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL NEUROSCIENCE MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL NEUROSCIENCE MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL NEUROSCIENCE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 120. AMERICAS NEUROSCIENCE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 121. AMERICAS NEUROSCIENCE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 122. AMERICAS NEUROSCIENCE MARKET SIZE, BY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 123. AMERICAS NEUROSCIENCE MARKET SIZE, BY IMAGING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 124. AMERICAS NEUROSCIENCE MARKET SIZE, BY MONITORING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 125. AMERICAS NEUROSCIENCE MARKET SIZE, BY THERAPEUTIC DEVICES, 2018-2032 (USD MILLION)
  • TABLE 126. AMERICAS NEUROSCIENCE MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 127. AMERICAS NEUROSCIENCE MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 128. AMERICAS NEUROSCIENCE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 129. AMERICAS NEUROSCIENCE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 130. AMERICAS NEUROSCIENCE MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 131. AMERICAS NEUROSCIENCE MARKET SIZE, BY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 132. AMERICAS NEUROSCIENCE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 133. NORTH AMERICA NEUROSCIENCE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 134. NORTH AMERICA NEUROSCIENCE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 135. NORTH AMERICA NEUROSCIENCE MARKET SIZE, BY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 136. NORTH AMERICA NEUROSCIENCE MARKET SIZE, BY IMAGING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 137. NORTH AMERICA NEUROSCIENCE MARKET SIZE, BY MONITORING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 138. NORTH AMERICA NEUROSCIENCE MARKET SIZE, BY THERAPEUTIC DEVICES, 2018-2032 (USD MILLION)
  • TABLE 139. NORTH AMERICA NEUROSCIENCE MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 140. NORTH AMERICA NEUROSCIENCE MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 141. NORTH AMERICA NEUROSCIENCE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 142. NORTH AMERICA NEUROSCIENCE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 143. NORTH AMERICA NEUROSCIENCE MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 144. NORTH AMERICA NEUROSCIENCE MARKET SIZE, BY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 145. NORTH AMERICA NEUROSCIENCE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 146. LATIN AMERICA NEUROSCIENCE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 147. LATIN AMERICA NEUROSCIENCE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 148. LATIN AMERICA NEUROSCIENCE MARKET SIZE, BY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 149. LATIN AMERICA NEUROSCIENCE MARKET SIZE, BY IMAGING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 150. LATIN AMERICA NEUROSCIENCE MARKET SIZE, BY MONITORING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 151. LATIN AMERICA NEUROSCIENCE MARKET SIZE, BY THERAPEUTIC DEVICES, 2018-2032 (USD MILLION)
  • TABLE 152. LATIN AMERICA NEUROSCIENCE MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 153. LATIN AMERICA NEUROSCIENCE MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 154. LATIN AMERICA NEUROSCIENCE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 155. LATIN AMERICA NEUROSCIENCE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 156. LATIN AMERICA NEUROSCIENCE MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 157. LATIN AMERICA NEUROSCIENCE MARKET SIZE, BY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 158. LATIN AMERICA NEUROSCIENCE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPE, MIDDLE EAST & AFRICA NEUROSCIENCE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPE, MIDDLE EAST & AFRICA NEUROSCIENCE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPE, MIDDLE EAST & AFRICA NEUROSCIENCE MARKET SIZE, BY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPE, MIDDLE EAST & AFRICA NEUROSCIENCE MARKET SIZE, BY IMAGING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPE, MIDDLE EAST & AFRICA NEUROSCIENCE MARKET SIZE, BY MONITORING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPE, MIDDLE EAST & AFRICA NEUROSCIENCE MARKET SIZE, BY THERAPEUTIC DEVICES, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPE, MIDDLE EAST & AFRICA NEUROSCIENCE MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPE, MIDDLE EAST & AFRICA NEUROSCIENCE MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPE, MIDDLE EAST & AFRICA NEUROSCIENCE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPE, MIDDLE EAST & AFRICA NEUROSCIENCE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPE, MIDDLE EAST & AFRICA NEUROSCIENCE MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPE, MIDDLE EAST & AFRICA NEUROSCIENCE MARKET SIZE, BY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPE, MIDDLE EAST & AFRICA NEUROSCIENCE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPE NEUROSCIENCE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPE NEUROSCIENCE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPE NEUROSCIENCE MARKET SIZE, BY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPE NEUROSCIENCE MARKET SIZE, BY IMAGING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPE NEUROSCIENCE MARKET SIZE, BY MONITORING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPE NEUROSCIENCE MARKET SIZE, BY THERAPEUTIC DEVICES, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPE NEUROSCIENCE MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPE NEUROSCIENCE MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPE NEUROSCIENCE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPE NEUROSCIENCE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPE NEUROSCIENCE MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPE NEUROSCIENCE MARKET SIZE, BY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPE NEUROSCIENCE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 185. MIDDLE EAST NEUROSCIENCE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 186. MIDDLE EAST NEUROSCIENCE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 187. MIDDLE EAST NEUROSCIENCE MARKET SIZE, BY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 188. MIDDLE EAST NEUROSCIENCE MARKET SIZE, BY IMAGING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 189. MIDDLE EAST NEUROSCIENCE MARKET SIZE, BY MONITORING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 190. MIDDLE EAST NEUROSCIENCE MARKET SIZE, BY THERAPEUTIC DEVICES, 2018-2032 (USD MILLION)
  • TABLE 191. MIDDLE EAST NEUROSCIENCE MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 192. MIDDLE EAST NEUROSCIENCE MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 193. MIDDLE EAST NEUROSCIENCE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 194. MIDDLE EAST NEUROSCIENCE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 195. MIDDLE EAST NEUROSCIENCE MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 196. MIDDLE EAST NEUROSCIENCE MARKET SIZE, BY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 197. MIDDLE EAST NEUROSCIENCE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 198. AFRICA NEUROSCIENCE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 199. AFRICA NEUROSCIENCE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 200. AFRICA NEUROSCIENCE MARKET SIZE, BY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 201. AFRICA NEUROSCIENCE MARKET SIZE, BY IMAGING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 202. AFRICA NEUROSCIENCE MARKET SIZE, BY MONITORING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 203. AFRICA NEUROSCIENCE MARKET SIZE, BY THERAPEUTIC DEVICES, 2018-2032 (USD MILLION)
  • TABLE 204. AFRICA NEUROSCIENCE MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 205. AFRICA NEUROSCIENCE MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 206. AFRICA NEUROSCIENCE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 207. AFRICA NEUROSCIENCE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 208. AFRICA NEUROSCIENCE MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 209. AFRICA NEUROSCIENCE MARKET SIZE, BY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 210. AFRICA NEUROSCIENCE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 211. ASIA-PACIFIC NEUROSCIENCE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 212. ASIA-PACIFIC NEUROSCIENCE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 213. ASIA-PACIFIC NEUROSCIENCE MARKET SIZE, BY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 214. ASIA-PACIFIC NEUROSCIENCE MARKET SIZE, BY IMAGING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 215. ASIA-PACIFIC NEUROSCIENCE MARKET SIZE, BY MONITORING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 216. ASIA-PACIFIC NEUROSCIENCE MARKET SIZE, BY THERAPEUTIC DEVICES, 2018-2032 (USD MILLION)
  • TABLE 217. ASIA-PACIFIC NEUROSCIENCE MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 218. ASIA-PACIFIC NEUROSCIENCE MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 219. ASIA-PACIFIC NEUROSCIENCE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 220. ASIA-PACIFIC NEUROSCIENCE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 221. ASIA-PACIFIC NEUROSCIENCE MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 222. ASIA-PACIFIC NEUROSCIENCE MARKET SIZE, BY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 223. ASIA-PACIFIC NEUROSCIENCE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 224. GLOBAL NEUROSCIENCE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 225. ASEAN NEUROSCIENCE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 226. ASEAN NEUROSCIENCE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 227. ASEAN NEUROSCIENCE MARKET SIZE, BY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 228. ASEAN NEUROSCIENCE MARKET SIZE, BY IMAGING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 229. ASEAN NEUROSCIENCE MARKET SIZE, BY MONITORING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 230. ASEAN NEUROSCIENCE MARKET SIZE, BY THERAPEUTIC DEVICES, 2018-2032 (USD MILLION)
  • TABLE 231. ASEAN NEUROSCIENCE MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 232. ASEAN NEUROSCIENCE MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 233. ASEAN NEUROSCIENCE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 234. ASEAN NEUROSCIENCE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 235. ASEAN NEUROSCIENCE MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 236. ASEAN NEUROSCIENCE MARKET SIZE, BY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 237. ASEAN NEUROSCIENCE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 238. GCC NEUROSCIENCE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 239. GCC NEUROSCIENCE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 240. GCC NEUROSCIENCE MARKET SIZE, BY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 241. GCC NEUROSCIENCE MARKET SIZE, BY IMAGING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 242. GCC NEUROSCIENCE MARKET SIZE, BY MONITORING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 243. GCC NEUROSCIENCE MARKET SIZE, BY THERAPEUTIC DEVICES, 2018-2032 (USD MILLION)
  • TABLE 244. GCC NEUROSCIENCE MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 245. GCC NEUROSCIENCE MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 246. GCC NEUROSCIENCE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 247. GCC NEUROSCIENCE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 248. GCC NEUROSCIENCE MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 249. GCC NEUROSCIENCE MARKET SIZE, BY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 250. GCC NEUROSCIENCE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 251. EUROPEAN UNION NEUROSCIENCE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 252. EUROPEAN UNION NEUROSCIENCE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 253. EUROPEAN UNION NEUROSCIENCE MARKET SIZE, BY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 254. EUROPEAN UNION NEUROSCIENCE MARKET SIZE, BY IMAGING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 255. EUROPEAN UNION NEUROSCIENCE MARKET SIZE, BY MONITORING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 256. EUROPEAN UNION NEUROSCIENCE MARKET SIZE, BY THERAPEUTIC DEVICES, 2018-2032 (USD MILLION)
  • TABLE 257. EUROPEAN UNION NEUROSCIENCE MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 258. EUROPEAN UNION NEUROSCIENCE MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 259. EUROPEAN UNION NEUROSCIENCE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 260. EUROPEAN UNION NEUROSCIENCE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 261. EUROPEAN UNION NEUROSCIENCE MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 262. EUROPEAN UNION NEUROSCIENCE MARKET SIZE, BY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 263. EUROPEAN UNION NEUROSCIENCE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 264. BRICS NEUROSCIENCE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 265. BRICS NEUROSCIENCE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 266. BRICS NEUROSCIENCE MARKET SIZE, BY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 267. BRICS NEUROSCIENCE MARKET SIZE, BY IMAGING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 268. BRICS NEUROSCIENCE MARKET SIZE, BY MONITORING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 269. BRICS NEUROSCIENCE MARKET SIZE, BY THERAPEUTIC DEVICES, 2018-2032 (USD MILLION)
  • TABLE 270. BRICS NEUROSCIENCE MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 271. BRICS NEUROSCIENCE MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 272. BRICS NEUROSCIENCE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 273. BRICS NEUROSCIENCE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 274. BRICS NEUROSCIENCE MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 275. BRICS NEUROSCIENCE MARKET SIZE, BY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 276. BRICS NEUROSCIENCE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 277. G7 NEUROSCIENCE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 278. G7 NEUROSCIENCE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 279. G7 NEUROSCIENCE MARKET SIZE, BY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 280. G7 NEUROSCIENCE MARKET SIZE, BY IMAGING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 281. G7 NEUROSCIENCE MARKET SIZE, BY MONITORING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 282. G7 NEUROSCIENCE MARKET SIZE, BY THERAPEUTIC DEVICES, 2018-2032 (USD MILLION)
  • TABLE 283. G7 NEUROSCIENCE MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 284. G7 NEUROSCIENCE MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 285. G7 NEUROSCIENCE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 286. G7 NEUROSCIENCE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 287. G7 NEUROSCIENCE MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 288. G7 NEUROSCIENCE MARKET SIZE, BY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 289. G7 NEUROSCIENCE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 290. NATO NEUROSCIENCE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 291. NATO NEUROSCIENCE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 292. NATO NEUROSCIENCE MARKET SIZE, BY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 293. NATO NEUROSCIENCE MARKET SIZE, BY IMAGING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 294. NATO NEUROSCIENCE MARKET SIZE, BY MONITORING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 295. NATO NEUROSCIENCE MARKET SIZE, BY THERAPEUTIC DEVICES, 2018-2032 (USD MILLION)
  • TABLE 296. NATO NEUROSCIENCE MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 297. NATO NEUROSCIENCE MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 298. NATO NEUROSCIENCE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 299. NATO NEUROSCIENCE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 300. NATO NEUROSCIENCE MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 301. NATO NEUROSCIENCE MARKET SIZE, BY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 302. NATO NEUROSCIENCE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 303. GLOBAL NEUROSCIENCE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 304. UNITED STATES NEUROSCIENCE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 305. UNITED STATES NEUROSCIENCE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 306. UNITED STATES NEUROSCIENCE MARKET SIZE, BY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 307. UNITED STATES NEUROSCIENCE MARKET SIZE, BY IMAGING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 308. UNITED STATES NEUROSCIENCE MARKET SIZE, BY MONITORING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 309. UNITED STATES NEUROSCIENCE MARKET SIZE, BY THERAPEUTIC DEVICES, 2018-2032 (USD MILLION)
  • TABLE 310. UNITED STATES NEUROSCIENCE MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 311. UNITED STATES NEUROSCIENCE MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 312. UNITED STATES NEUROSCIENCE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 313. UNITED STATES NEUROSCIENCE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 314. UNITED STATES NEUROSCIENCE MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 315. UNITED STATES NEUROSCIENCE MARKET SIZE, BY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 316. UNITED STATES NEUROSCIENCE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 317. CHINA NEUROSCIENCE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 318. CHINA NEUROSCIENCE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 319. CHINA NEUROSCIENCE MARKET SIZE, BY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 320. CHINA NEUROSCIENCE MARKET SIZE, BY IMAGING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 321. CHINA NEUROSCIENCE MARKET SIZE, BY MONITORING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 322. CHINA NEUROSCIENCE MARKET SIZE, BY THERAPEUTIC DEVICES, 2018-2032 (USD MILLION)
  • TABLE 323. CHINA NEUROSCIENCE MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 324. CHINA NEUROSCIENCE MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 325. CHINA NEUROSCIENCE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 326. CHINA NEUROSCIENCE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 327. CHINA NEUROSCIENCE MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 328. CHINA NEUROSCIENCE MARKET SIZE, BY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 329. CHINA NEUROSCIENCE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)